Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089

International Journal of Oncology

Volumn 13, Issue 1, 1998, Pages 137-143

  Huynh, Hung ^a   Pollak, Michael ^a   Zhang, Jian Chun ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Inhibition; Prostate cancer; Stability

Indexed keywords

ANTIBODY; CALCITRIOL; MESSENGER RNA; SEOCALCITOL; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CALCITRIOL; CELL DIVISION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR II; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0031860551     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.1.137     Document Type: Article

References (45)

1. Reichel H, Koeffler HP and Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991, 1989.
2. DeLuca HF: The vitamin D story: a collaborative effort of basic science and clinical medicine. (Review). FASEB J 2: 224-236, 1988.
3. Eisman JA, Martin TJ, MacIntyre I, Frampton RJ, Moseley JM and Whitehead R: 1,25-Dihydroxyvitamin D3 receptor in a cultured human breast cancer cell line (MCF 7 cells). Biochem Biophys Res Commun 93: 9-15, 1980.
4. Colston K, Colston MJ, Fieldsteel AH and Feldman D: 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res 42: 856-859, 1982.
5. Colston KW, Berger U and Coombes RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1: 188-191, 1989.
6. Walters MR: Newly identified actions of the vitamin D endocrine system. (Review). Endocr Rev 13: 719-764, 1992.
7. Colston K, Hirst M, Feldman D and Hirt M: Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology 107: 1916-1922, 1980.
8. Pike JW, Gooze LL and Haussler MR: Biochemical evidence for 1,25-dihydroxyvitamin D receptor macromolecules in parathyroid, pancreatic, pituitary, and placental tissues. Life Sci 26: 407-414, 1980.
9. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ and Evans SR: Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31: 191-202, 1994.
10. 3. Endocrinology 13: 20-26, 1995.
11. Schwartz GG and Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307-1311, 1990.
12. Kawaura A, Tanida N, Sawada K, Oda M and Shimoyama T: Supplemental administration of 1 alpha-hydroxyvitamin D3 inhibits promotion by intrarectal instillation of lithocholic acid in N-methyl-N-nitrosourea-induced colonic tumorigenesis in rats. Carcinogenesis 10: 647-649, 1989.
13. Chida K, Hashiba H, Fukushima M, Suda T and Kuroki T: Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3. Cancer Res 45: 5426-5430, 1985.
14. Wood AW, Chang RL, Huang MT, Uskokovic M and Conney AH: 1 alpha,25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 116: 605-611, 1983.
15. Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, Nishii Y, DeLuca HF and Suda T: 1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 80: 201-204, 1983.
16. Eisman JA, Barkla DH and Tutton PJ: Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 47: 21-25, 1987.
17. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960, 1993.
18. Rajah R, Valentinis B and Cohen P: Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-ß1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272: 12181-12188, 1997.
19. Colston KW, MacKay AG, James SY, Binderup L, Chander S and Coombes RC: EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44: 2273-2280, 1992.
20. Zhou JY, Norman AW, Chen DL, Sun GW, Uskokovic M and Koeffler HP: 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87: 3929-3932, 1990.
21. Elstner E, LinkerIsraeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M and Koeffler HP: 20-epivitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55: 2822-2830, 1995.
22. James SY, MacKay AG, Binderup L and Colston KW: Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 141: 555-563, 1994.
23. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E and Ikeda K: A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837, 1991.
24. 3 analog with potent ability to induce HL60 cell differentiation without modulating calcium metabolism. Blood 78: 75-82, 1991.
25. Bikle DD: Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. (Review). Endocr Rev 13: 765-784, 1992.
26. Abe J, Takita Y, Nakano T, Miyaura C, Suda T and Nishii Y: A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 124: 2645-2647, 1989.
27. Guenette RS and Tenniswood M: The role of growth factors in the suppression of active cell death in the prostate: a hypothesis. Biochem Cell Biol 72: 553-559, 1994.
28. Cohen P, Peehl DM, Lamson G and Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73: 401-407, 1991.
29. Iwamura M, Sluss PM, Cassmento JB, Cockett ATK, Casamento JB and Cockett AT: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252, 1993.
30. Steiner MS: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy (Review). J Urol 153: 1085-1096, 1995.
31. Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
32. Oh YM, Nagalla SR, Yamanaka Y, Kim HS, Wilson E and Rosenfeld RG: Synthesis and characterization of insulin-like growth factor binding protein (IGFBP)-7-recombinant human MAC25 protein specifically binds IGF-I and II. J Biol Chem 271: 30322-30325, 1996.
33. Cohen P, Peehl DM and Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994.
34. Angelloz-Nicoud P and Binoux M: Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136: 5485-5492, 1995.
35. Oh Y, Muller HL, Lamson G and Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J Biol Chem 268: 14964-14971, 1993.
36. Huynh HT, Yang X and Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-1021, 1996.
37. Pratt SE and Pollak M: Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of IGF binding proteins in conditioned media. Cancer Res 53: 5193-5198, 1993.
38. Huynh HT and Pollak M: Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine IGF binding protein 3 gene expression. Cancer Res 54: 3115-3119, 1994.
39. Huynh HT and Pollak M: IGF-1 gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585-5588, 1993.
40. Spratt SK, Tatsuno GP, Yamanaka MK, Ark BC, Detmer J, Mascaremjas D, Flynn J, TalkingtonVerser C and Spencer EM: Cloning and expression of human insulin-like growth factor binding protein 3. Growth Factors 3: 63-72, 1990.
41. Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeroppulos MH, Xiao H, Merril CR, Wu A, Olde B, Moreno RF, Kerlavage AR, McCombie WR and Venter JC: Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252: 1651-1656, 1991.
42. Noda M, Yoon K and Rodan GA: Cyclic AMP-mediated stabilization of osteocalcin mRNA in rat osteoblast-like cells treated with parathyroid hormone. J Biol Chem 263: 18574-18577, 1988.
43. Huynh HT, Yang X and Pollak M: A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 7: 1501-1506, 1996.
44. Berger U, McClelland RA, Wilson P, Greene GL, Haussier MR, Pike JW, Colston K, Easton D and Coombes RC: Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51: 239-244, 1991.
45. Huynh HT, Tetenes E, Wallace L and Pollak M: In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 53: 1727-1730, 1993.